6.73
price down icon3.72%   -0.26
after-market After Hours: 6.90 0.17 +2.53%
loading
Immunome Inc stock is traded at $6.73, with a volume of 6.31M. It is down -3.72% in the last 24 hours and down -28.40% over the past month.
See More
Previous Close:
$6.99
Open:
$6.76
24h Volume:
6.31M
Relative Volume:
6.17
Market Cap:
$633.00M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-2.0322
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
-17.42%
1M Performance:
-28.40%
6M Performance:
-53.97%
1Y Performance:
-72.73%
1-Day Range:
Value
$6.41
$6.855
1-Week Range:
Value
$6.41
$8.24
52-Week Range:
Value
$6.41
$24.86

Immunome Inc Stock (IMNM) Company Profile

Name
Name
Immunome Inc
Name
Phone
610-321-3700
Name
Address
18702 N. CREEK PARKWAY, BOTHELL
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
IMNM's Discussions on Twitter

Compare IMNM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IMNM
Immunome Inc
6.73 633.00M 0 -106.81M -8.40M -3.3117
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Immunome Inc Stock (IMNM) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-08-24 Initiated Stephens Overweight
May-31-24 Initiated Piper Sandler Overweight
Apr-30-24 Initiated JP Morgan Overweight
Apr-15-24 Initiated Guggenheim Buy
Jan-29-24 Initiated Leerink Partners Outperform
Dec-19-23 Initiated Wedbush Outperform
Oct-29-21 Initiated Cantor Fitzgerald Overweight
View All

Immunome Inc Stock (IMNM) Latest News

pulisher
Mar 28, 2025

Immunome stock hits 52-week low at $6.94 amid market challenges By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Immunome stock hits 52-week low at $6.94 amid market challenges - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Immunome (NASDAQ:IMNM) Stock Price Up 4.4% After Insider Buying Activity - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Immunome (IMNM) Stock Climbs as Executives Increase Holdings - GuruFocus

Mar 27, 2025
pulisher
Mar 27, 2025

Immunome director Jean Jacques Bienaime acquires $60,684 in stock - Investing.com

Mar 27, 2025
pulisher
Mar 26, 2025

Immunome CEO Clay Siegall buys $999k in stock By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Immunome director Jean Jacques Bienaime acquires $60,684 in stock By Investing.com - Investing.com UK

Mar 26, 2025
pulisher
Mar 26, 2025

Immunome CEO Clay Siegall buys $999k in stock - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Immunome stock rises after insider purchase (IMNM:NASDAQ) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

Immunome director Jean Jacques Bienaime purchases $57,470 in stock By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Charles Schwab Investment Management Inc. Increases Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Immunome CTO Philip Tsai purchases $103,566 in stock By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Immunome director Jean Jacques Bienaime purchases $57,470 in stock - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

Immunome CTO Philip Tsai purchases $103,566 in stock - Investing.com

Mar 25, 2025
pulisher
Mar 24, 2025

Bank of New York Mellon Corp Has $1.31 Million Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

Wedbush Has Positive Estimate for Immunome Q1 Earnings - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Immunome’s (IMNM) “Outperform” Rating Reiterated at Wedbush - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Guggenheim Has Lowered Expectations for Immunome (NASDAQ:IMNM) Stock Price - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Stephens Reiterates Overweight Rating for Immunome (NASDAQ:IMNM) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Trading (IMNM) With Integrated Risk Controls - news.stocktradersdaily.com

Mar 21, 2025
pulisher
Mar 21, 2025

Immunome Full Year 2024 Earnings: Misses Expectations - Yahoo

Mar 21, 2025
pulisher
Mar 21, 2025

Immunome’s 2024 Financial Results and Pipeline Progress - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Immunome stock target cut to $25 by Guggenheim - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Immunome (IMNM) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Immunome earnings missed by $0.45, revenue fell short of estimates - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Immunome 2024 Net Loss Narrows -March 19, 2025 at 05:07 pm EDT - Marketscreener.com

Mar 19, 2025
pulisher
Mar 19, 2025

Immunome Inc. (IMNM) reports earnings - Quartz

Mar 19, 2025
pulisher
Mar 19, 2025

Immunome Inc. SEC 10-K Report - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

Immunome Reports Full Year 2024 Financial Results and Provides Business Update - The Bakersfield Californian

Mar 19, 2025
pulisher
Mar 19, 2025

Immunome stock hits 52-week low at $8.37 amid market challenges - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone - Stock Titan

Mar 19, 2025
pulisher
Mar 18, 2025

Immunome stock hits 52-week low at $8.37 amid market challenges By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

With 59% ownership of the shares, Immunome, Inc. (NASDAQ:IMNM) is heavily dominated by institutional owners - Yahoo

Mar 17, 2025
pulisher
Mar 15, 2025

Immunome, Inc. (NASDAQ:IMNM) Receives $27.17 Average PT from Analysts - MarketBeat

Mar 15, 2025
pulisher
Mar 15, 2025

Lifesci Capital Predicts Immunome FY2024 Earnings - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Q1 Earnings Forecast for Immunome Issued By Lifesci Capital - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $27.17 - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Immunome (NASDAQ:IMNM) Now Covered by Lifesci Capital - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

LifeSci Capital Initiates Coverage of Immunome (IMNM) with Outperform Recommendation - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Immunome’s (IMNM) “Outperform” Rating Reaffirmed at Wedbush - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Immunome stock hits 52-week low at $8.53 amid market challenges - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

Immunome stock hits 52-week low at $8.53 amid market challenges By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Immunome doses first patient in early-stage trial of its experimental cancer treatment -March 10, 2025 at 08:23 am EDT - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Joplin Globe

Mar 10, 2025
pulisher
Mar 06, 2025

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 6, 2025 - BioSpace

Mar 06, 2025
pulisher
Mar 06, 2025

Immunome's Latest Talent Investment: 49,000 Share Options Awarded to Key New Hires - Stock Titan

Mar 06, 2025
pulisher
Feb 28, 2025

Immunome (NASDAQ:IMNM) Sets New 52-Week LowHere's Why - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Handelsbanken Fonder AB - MarketBeat

Feb 28, 2025

Immunome Inc Stock (IMNM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):